Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Key Proteins in Urine Samples Detect Preeclampsia

By LabMedica International staff writers
Posted on 15 Dec 2010
Protein biomarkers in the urine of women in the early stage of pregnancy can determine whether they will develop preeclampsia. More...


A simple measurement of key proteins in spot urine samples and changes in the urinary protein profile early in pregnancy might predict the development of preeclampsia, which typically does not appear until later in pregnancy.

Preeclampsia is a condition in pregnancy characterized by abrupt hypertension (a sharp rise in blood pressure), albuminuria (leakage of large amounts of the protein albumin into the urine) and edema (swelling) of the hands, feet, and face. Preeclampsia is the most common complication of pregnancy.

Scientists from the Leicester General Hospital, (Leicester, UK), analyzed urine samples obtained before 20 weeks of gestation from 145 pregnant women who either did or did not develop preeclampsia. The prospective longitudinal study involved pregnant women from a high-risk obstetric outpatient clinic. Urine samples were taken and analyzed the same day with surface enhanced laser desorption/ionization time-of-flight mass spectrometry.

After delivery, patients were categorized as having had preeclampsia or a normal pregnancy. A spectral analysis of the urine samples of preeclampsia and nonpreeclampsia pregnancies taken before 20 weeks of gestation was performed with an artificial neural network algorithm and multivariate nonlinear regression. A random sampling of 50 test datasets validated the model. The results identified a panel of five protein peaks that predicted preeclampsia with 92% accuracy; the test datasets showed a sensitivity of 87% and a specificity of 82%.

Matt Hall, MBChB, of the University of Leicester (Leicester, UK), and the lead author of the study, said, "Given that proteinuria is a key diagnostic and prognostic factor in preeclampsia, the renal morphological changes occur early in the disease, and the initiation of this process begins four to five months before the clinical manifestations."

Arlene Chapman, MD, professor of medicine at Emory School of Medicine (Atlanta, GA, USA), said, "Numerous biomarkers have been investigated to try to detect the condition early, most notably soluble FMS-like tyrosine kinase and soluble endoglin, peptides that are produced by the placenta. The identification of a urinary proteomic fingerprint could help with the diagnosis.” The study was presented on November 19, 2010, at the Annual Meeting of the American Society of Nephrology held in Denver (CO, USA).

Related Links:
Leicester General Hospital
Emory School of Medicine
University of Leicester



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.